Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Targovax ASA ( (GB:0RIS) ).
Circio Holding ASA announced an upcoming webcast where CTO Dr. Thomas B Hansen will present the latest in vitro and in vivo results of their circVec circular RNA expression platform, highlighting its potential in AAV gene therapy. CEO Dr. Erik D Wiklund will also provide a corporate update, which could impact the company’s strategic direction and stakeholder interests.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing novel circular RNA expression technology for gene and cell therapy. The company has established a unique circular RNA (circRNA) vector expression technology, known as the circVec platform, which is designed for efficient biogenesis of multifunctional circRNA inside target cells. This platform has applications in genetic medicine, cell therapy, and chronic disease, offering significantly increased RNA half-life and enhanced protein expression compared to conventional mRNA-based systems.
YTD Price Performance: 33.52%
Average Trading Volume: 2,977,462
Current Market Cap: NOK136.2M
Find detailed analytics on 0RIS stock on TipRanks’ Stock Analysis page.